EP1663174A1 - Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine - Google Patents

Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine

Info

Publication number
EP1663174A1
EP1663174A1 EP04761472A EP04761472A EP1663174A1 EP 1663174 A1 EP1663174 A1 EP 1663174A1 EP 04761472 A EP04761472 A EP 04761472A EP 04761472 A EP04761472 A EP 04761472A EP 1663174 A1 EP1663174 A1 EP 1663174A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition according
fenofibrate
lowering agent
homocysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04761472A
Other languages
German (de)
English (en)
Inventor
Francis Vanderbist
Philippe Baudier
Arthur Deboeck
Antonio Sereno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galephar MF
Original Assignee
Galephar MF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar MF filed Critical Galephar MF
Publication of EP1663174A1 publication Critical patent/EP1663174A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a single unit pharmaceutical composition 5 comprising fenofibrate and at least a homocysteine lowering agent useful to reduce the plasma levels of homocysteine in patients to whom fibrates are administered.
  • the homocysteine lowering agent is selected from the group consisting of folic acid, vitamin B12, Vitamin B6 and Betaine.
  • the homocysteine lowering agent is formulated as a modified release 10 composition i.e.delayed or extended release
  • composition of the present invention may be administered to patients once a day.
  • compositions of the present invention are further characterised that the single dosage unit contains amounts of fenofibrate comprised between 15 25mg and 300mg and therapeutic amounts of one or several modified release homocysteine lowering agents
  • homocysteine in patients is known as hyperhomocysteinemia and can be divided into three classes: Severe (homocysteine plasma concentration > 100 ⁇ mol/L), moderate (25 to 100 ⁇ mol/L), or mild (16 to 24 ⁇ mol/L).
  • Severe hyperhomocysteinemia is usually caused by a homozygous deficiency of the enzyme cystathionine ⁇ -synthase. Affected persons have severe mental retardation, ectopic lens, skeletal abnormalities, and severe premature arterial and venous thrombotic disease.
  • Homocysteine is a highly reactive amino acid containing a free sulfhydryl group. It can promote oxidation of low-density lipo-protein (LDL) cholesterol and presumably is toxic to vascular endothelium. It may also inhibit thrombomodulin expression and protein C activation and suppress endothelial heparan sulfate expression, both of these effects lead to hypercoagulability.
  • LDL low-density lipo-protein
  • homocysteine was shown to enhance the binding of lipoprotein(a), and atherogenic lipoprotein to fibrin, which may provide a link between hyperhomocysteinemia, thrombosis, and premature atherosclerosis. The vascular damage caused by high homocysteine levels leads to arterial and venous thrombosis and, perhaps, accelerated atherosclerosis.
  • Fenofibrate pertain to the lipid lowering family drugs of fibrates.
  • lipid-modifying effects of fenofibrate are mediated via the activation of the peroxisome proliferator-activated receptors (PPARs).
  • PPARs peroxisome proliferator-activated receptors
  • Fenofibrate reduce plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) and very-low-density lipoprotein (VLDL) cholesterol levels, and increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) Al and Apo All levels in patients with dyslipidaemia.
  • Fenofibrate also reduce plasma fibrinogen levels in both normolipidemic individuals and those with dyslipidemia, and is significantly more effective in that reduction than Simvastatin, Atorvastatin or Pravastatin. This is of significance since increased levels of fibrinogen or plasminogen activator inhibitor (PAI-1) are associated with an increased risk of atherosclerosis and coronary heart disease (CHD).
  • Fenofibrate has also demonstrated a very important activity in reducing the levels of the inflammatory marker C reactive protein (CRP)., which has been recognized to have a negative effect on the evolution of the pathogenesis of atherosclerosis and coronary heart diseases.
  • CRP C reactive protein
  • Fenofibrate or p-(4-chlorobenzoyl)-phenoxy isobutyrate isopropyl ester is useful for the treatment of adult patients with very high elevations of serum triglyceride levels and/or cholesterol levels.
  • the usual daily dosage is 50 to 300mg which is administered in one or two doses.
  • Fenofibrate absorbed as fenofibric acid, resulting from the hydrolysis of fenofibrate, is extensively bound to plasma albumin.
  • Fenofibric acid has a Tmax (time to peak plasma level) of 3-6 hours after oral administration of a conventional marketed form such as Lipanthyl ® tablet or Fenogal ® capsule.
  • the plasma half-life is about 20 hours.
  • Fenofibric acid is excreted predominantly in the urine, mainly as the glucuronide conjugate, but also as a reduced form of fenofibric acid and its glucuronides.
  • a homocysteine lowering agent is defined as a substance able to decrease plasma levels of homocysteine in humans in such a need. Examples of those homocysteine lowering agents are: Folic acid, vitamin B6, vitamin B12 and Betaine.
  • vitamin supplementation with folic acid and vitamin B12 effectively reduces the plasma homocysteine levels.
  • an oral single unit pharmaceutical composition consisting of the combination of a therapeutic effective amount of fibrate derivative with at least an effective amount of lowering homocysteine agent or a mixture of such lowering homocysteine agents, the release of this homocysteine lowering agent(s) being controlled in order to better suit to the release of fenofibrate.
  • controlled release composition we mean any composition which is not an immediate release composition (also called convetional form).
  • controlled release compositions are compositions containing an agent being capable of modifying the release of the compound (when compared to immediate release forms) either by delaying it or by prolonging it.
  • examples of such formulations are coated tablets or matrix tablets, coated or matrix beads, osmotic pumps, bioadhesive forms, multilayer tablets, fatty matrix,...
  • compositions containing folic acid, vitamine B12 and vitamine B6 of mixtures thereof are available on the market as immediate release forms i.e. forms releasing the compound immediately in the gastro-intestinal tract. Altough the value of Tmax of those substances may vary depending on the compound considered, the tmax is often of 0.5 to 2 hours after oral administration.
  • the object of the present invention is to dispose, in the same pharmaceutical form, of a combination of fenofibrate and an homocysteine lowering agent, said form releasing fenofibrate in a similar way as the compositions of fenofibrate available on the market (Tmax of 3-6 hours) and the homocysteine lowering agent in a modified release in order be as close as possible to fenofibrate's release (Tmax at least greater than 1 hourn preferably greater than 2 hours).
  • a single unit form is a pharmaceutical form containing both the fibrate derivative and the modified release homocysteine lowering agent in such a way that the patient can swallow the said pharmaceutical form in a single intake.
  • the present invention relates to a pharmaceutical composition containing a fibrate and able, to some extent, to prevent the increase of homocysteine plasma levels caused by the fibrate.
  • a capsule containing a coated, or uncoated or multilayer tablet of a modified release homocysteine lowering agent with a semi-solid composition of fenofibrate is suitable.
  • capsules containing the modified release homocysteine lowering agent under the form of pellets or tablets and fenofibrate formulated as a paste, semi-solid tablet, granulated powder or pellets, coated or uncoated tablets, but always combined in a single unit form.
  • the modified release form of homocysteine lowering agent release may be a delayed form such as an enteric tablet or capsule, or a sustained release form (tablet or granules) or a form combining an immediate release form of the homocysteine lowering agent with a prolonged release form of the same homocysteine lowering agent.
  • the homocysteine lowering agent may also be present in the final composition as bilayer tablet where the homocysteine lowering agent is in the core (central layer or inner layer) of the tablet and the sustained release properties are conferred by the outer layer of the tablets.
  • This formulation presents the advantage to avoid any physical contact between the homocysteine lowering agent and fenofibrate, and hence to prevent any kind of chemical interaction between the two compounds.
  • this composition canenhac ethe stability properties of the homocysteine lowering agent within the final composition
  • fenofibrate present a relatively long elimination half-life, from 20 to 90 hours and some of vitamin B derivatives present a short half-life (folic acid : 3 hours)
  • the single unit final form can be a capsule containing a semi- solid formulation of fenofibrate, and a sustained release tablet (coated or not) containing the vitamin B derivative.
  • sustained release vitamin B formulations can be matrix tablets containing an hydrophilic or an hydrophobic polymer (or a mixture thereof), bilayer or mulilayer tablets, sustained release coated granules, matrix granules, etc,...
  • sustained release compositions of vitamins B derivatives the absorption window should be taken into account.
  • folic acid and vitamine B6 have their main absorption window in the proximal jejunum.
  • the sustained release of folic acid or vitamine B6 should therefore not be too slow because it should be delivered completely within the absorption window to keep an acceptable bioavailability.
  • sustained release formulations of folic acid should present a Tmax in vivo of between 1 and 10 hours, preferably between 2 and 8 hours, more preferably between 2 and 6 hours.
  • the dissolution rate is for instance of 0 to 50 % after 30 minutes, 5 to 75 % dissolved after 1 hour, 20 to 90 % dissolved after 2 hours, 50-95 % dissolved after 4 hours and more than 80 % dissolved after 8 hours.
  • the homocysteine lowering agent can be a combination of various homocysteine lowering agents such as, but not limited to, a combination of folic acid and vitamin B12 or a combination of folic acid and vitamin B6 or even a combination of folic acid with vitamin B12 and vitamin B6.
  • all of the homocysteine lowering agents are present as modified release forms or alternatively some of the homocysteine lowering agents are present as modified release forms and other are immediate release.
  • the homocysteine lowering agent can be formulated insuch a way that it presents a biphasic or multiphasic release what means that it, for instance, can present both immediate and sustained release properties.
  • a sustained release matrix tablet of folic acid may be further coated with an additional amount of folic acid (iwhich is release rapidly). This coated tablet is then put into a capsule with a semi-solid composition of fenofibrate to obtain the final composition of the present invention.
  • Example 1 example 1 a : Folic acid uncoated tablet
  • Folic acid, lactose monohydrate, cellulose microcrystalline and povidone K30 were blended in a planetary mixer for about 5 to 10 minutes until an homogeneous blend is obtained. While under agitation, a solution containing the water for granulation is added to granulate the powders. The granules obtained are dried at about 40°C for about 5 hours. Thereafter the dried granules are screened through a 1.0 mm sieve, and further blended into a planetary mixer for about 2 minutes after the addition of the magnesium stearate and sodium starch glycolate. The final mix is compressed into tablets using a rotary compressing machine equipped with punches of the deep cup type with a diameter of 6.5mm.
  • the mean weight of the tablets is of about 180 mg, corresponding to tablets containing 1 mg of folic acid.
  • the tablet hardness is comprised between 4 and 6 kilopascals (Kp).
  • Example 1b coating of folic acid tablets Ingredient Name Amount [g]
  • the coating solution of examplelb is applied to the tablets from Example 1a using a pan coater.
  • the amount of coating applied is about 15 mg of dry coating (weight gain) per tablet.
  • ethylcellulose is the agent responsible of the prolonged release of folic acid.
  • Example 1 c semi-solid fenofibrate composition Amount
  • Fenofibrate powder 160 Lauroyl macrogolglyceride 240 (gelucire 44/14) Polyethylene glycol 20,000 48 Hydroxypropylcellulose 95.0 Sodium starch glycolate 20.0 Ascorbyl palmitate 1.0
  • Gelucire 44/14 and polyethylene glycol 20,000 are added to a mixer equipped with a double wall bowl. The mixer is started and the bowl is warmed at about 75°C. When the gelucire and the polyethylene glycols are molten, the other ingredients (Fenofibrate, hydroxypropyl cellulose, sodium starch glycolate and ascorbyl palmitate) are added while maintaining the temperature at about 70 - 75°C.
  • Example 1 Final composition
  • the combination product is obtained by filling, into size 0 elongated hard gelatin capsules, one tablet of Example 1a coated with 1 b and 564mg of the hot blend of Example 3. After filling, the capsules are cooled by placing them on trays between 4 and 8°C.
  • the capsules obtained contained 1 mg of folic acid and 160mg of fenofibrate. It should be noted that the matrix tablet obtained allow to deliver folic acid in a sustained release manner as demonstrated by the in vitro dissolution curve given hereinbelow.
  • Example 2a folic acid and vitamine b12 matrix tablets
  • Folic acid, Vitamin B12, Lactose monohydrate, cellulose microcrystalline and povidone K30 are blended in a planetary mixer for about 5 to 10 minutes until an homogeneous blend is obtained. While under agitation, an aqueous suspension of EUDRAGIT ® NE30D (polyacrylate dispersion 30 % which is the agent responsible for the controllled release) into the water for granulation is added to granulate the powders. The granules obtained are dried at about 40°C for about 5 hours. After the dried granules are screened through a 1.0 mm sieve, they are blended into a planetary mixer for about 2 minutes after the addition of the magnesium stearate and sodium starch glycolate.
  • EUDRAGIT ® NE30D polyacrylate dispersion 30 % which is the agent responsible for the controllled release
  • Example 2b fenofibrates granules
  • Fenofibrate, lactose, povidone and sodium lauryl sulfate are blended in a planetary mixer and water is added to granulate. After oven drying for about 5 hours at 50°C, the granules are screened through a 1mm sieve. After addition of crospovidone and the magnesium stearate the granules that are blended for an additional 3 minutes in the planetary mixer.
  • Example 3 500 mg of lubricated granules of Example 2b and a tablet of Example 2a are filled into 0 elongated hydroxypropylmethylcellulose capsules to produce a combination product containing 2 mg of folic acid, 0.5 mg of vitamin B12 and 160mg of fenofibrate.
  • Example 3 500 mg of lubricated granules of Example 2b and a tablet of Example 2a are filled into 0 elongated hydroxypropylmethylcellulose capsules to produce a combination product containing 2 mg of folic acid, 0.5 mg of vitamin B12 and 160mg of fenofibrate.
  • Example 3 500 mg of lubricated granules of Example 2b and a tablet of Example 2a are filled into 0 elongated hydroxypropylmethylcellulose capsules to produce a combination product containing 2 mg of folic acid, 0.5 mg of vitamin B12 and 160mg of fenofibrate.
  • Example 3a folic acid coated beads
  • Water is added to the blend of all the ingredients in a planetary mixer to granulate the powder.
  • the paste obtained is extruded and spheronized in order to obtain beads with a diameter of about 1mm.
  • the beads are tray dried in an oven at about 40°C for approximately 5 hours.
  • the beads are thereafter screened between 0.7mm and 1.4mm sieves.
  • Example 3a 500 g of beads from Example 3a are coated with 200 g of coating solution) of Example 1b using a fluid bed coater (Strea 1) equipped with a wurster column.
  • a combination formulation is produced by filling in a 00 hard gelatin capsules with 500 mg of Fenofibrate lubricated granules of Example 2b and 145 mg of folic acid beads of Example 3a.
  • the resulting combination formulation contained 5 mg of folic acid and Example 4 :
  • example 4a inner layer containing folic acid
  • example 4b outer layer (sustained release layer) Amount Ingredient Name [mg] / tablet
  • the diameter of the inner tablet is 6 mm and the hardness around 28-10 Kp
  • the bilayered tablet is obtaining by proceeding to the compression of the inner tablet and hence to proceed to the compression of the outlayer tablet around the inner tablet while mainting the inner tablet centrally such as after compression of the outer tablet, the inner tablet is no more visible.
  • the final composition of example 4 is obtained by combining in a size 0 elongated hard gelatin capsule, 564 mg of the semi-solid composition of fenofibrate of example 1c with the bilayer tablets cotnaining folic acid described hereinabove
  • the dissolution curve hereinbelow shows the extended release profile of the bilayer folic acid tablets in comparison to the core only.
  • the bilayer tablets clealry possess extended release properties due to the presence of stearic acid in the oute rlayer of the tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une préparation pharmaceutique orale abaissant le taux de lipides, qui comprend une première composition solide ou semi-solide renfermant elle-même un fénofibrate, et une seconde composition solide ou semi-solide comprenant une forme à libération modifiée d'un agent abaisseur de taux d'homocystéine.
EP04761472A 2003-08-05 2004-08-04 Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine Withdrawn EP1663174A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE0300132 2003-08-05
PCT/BE2004/000111 WO2005011642A1 (fr) 2003-08-05 2004-08-04 Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine

Publications (1)

Publication Number Publication Date
EP1663174A1 true EP1663174A1 (fr) 2006-06-07

Family

ID=34109531

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04761472A Withdrawn EP1663174A1 (fr) 2003-08-05 2004-08-04 Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine

Country Status (3)

Country Link
EP (1) EP1663174A1 (fr)
CA (1) CA2534660A1 (fr)
WO (1) WO2005011642A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113134086A (zh) * 2020-01-20 2021-07-20 深圳市长卿医学研究院 一种降血脂的药物组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (fr) 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
WO2006086856A1 (fr) 2005-02-15 2006-08-24 Messadek, Jallal Compositions therapeutiques combinees et leurs procedes d’utilisation
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
WO2008095263A1 (fr) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd Forme pharmaceutique contenant deux ou davantage de principes actifs pharmaceutiques sous des formes physiques différentes
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
WO2016050734A1 (fr) * 2014-09-30 2016-04-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons d'inhibiteurs de la recapture de la norépinéphrine et de la sérotonine et sources de folate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19910682B4 (de) * 1999-03-10 2004-09-02 Dierkes, Jutta, Dr. Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
CA2313504C (fr) * 1999-07-12 2007-05-29 Douglas P. Debernardi Acide folique sous formes posologiques solides
DE10004651A1 (de) * 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
WO2003013607A1 (fr) * 2001-08-07 2003-02-20 Galephar M/F Composition pharmaceutique orale contenant une combinaison de fenofibrate et d'un inhibiteur de hmg-coa reductase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005011642A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113134086A (zh) * 2020-01-20 2021-07-20 深圳市长卿医学研究院 一种降血脂的药物组合物
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Also Published As

Publication number Publication date
WO2005011642A1 (fr) 2005-02-10
WO2005011642A9 (fr) 2005-12-01
CA2534660A1 (fr) 2005-02-10

Similar Documents

Publication Publication Date Title
EP2341910B1 (fr) Formes posologiques à libération immédiate d'oxybate de sodium
US7229982B2 (en) Pharmaceutical formulation
RU2343905C2 (ru) Твердые дозированные формы, включающие фибрат и статин
US7741374B1 (en) Methods of use of fenofibric acid
JP2009500317A (ja) 放出特性改良医薬組成物およびその製造方法
JPH07558B2 (ja) モピダモール製剤
US20120045505A1 (en) Fixed dose drug combination formulations
WO2006037348A1 (fr) Compositions pharmaceutiques contenant du fenofibrate et une statine
EP1581194A2 (fr) Comprimé multicouche contenant de la pravastatine et de l'aspirine et procédé
US20070014846A1 (en) Pharmaceutical compositions comprising fenofibrate and atorvastatin
JP4740945B2 (ja) ＨＭＧ−ＣｏＡ還元酵素阻害剤の経口投与用徐放性製剤およびその製造方法
WO2005011642A1 (fr) Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine
US20150037414A1 (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
EP1651194B1 (fr) Compositions pharmaceutiques stables a liberation controlee contenant du fenofibrate et de la pravastatine
CA2582403A1 (fr) Compositions pharmaceutiques comprenant du fenofibrate et de l'atorvastatine
US20070160663A1 (en) Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent
WO2006037345A1 (fr) Compositions pharmaceutiques comprenant du fenofibrate et de la simvastatine
AU2003254428B2 (en) Stable controlled release pharmaceutical compositions containing Fenofibrate and Pravastatin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20060807

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080111